Literature DB >> 16364337

Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques.

Satomi Onoue1, Sumiko Iwasa, Takashi Kojima, Fumie Katoh, Kazuhiro Debari, Keitatsu Koh, Yoshihisa Matsuda, Takehiko Yajima.   

Abstract

Glucagon, a polypeptide hormone consisting of 29 amino acid residues, tends to form gel-like fibrillar aggregates, and the glucagon fibril, as well as other pathologically related fibrils including prion, amylin, and beta-amyloid, have been found to be cytotoxic through the activation of apoptotic signaling pathways. To understand the aggregation properties of glucagon fibril, we have characterized and compared the physicochemical properties of glucagon, secretin, a member of the glucagon superfamily, and amylin using analytical techniques including capillary electrophoresis (CE), circular dichroism (CD), FT-IR, FT-Raman, transmission electron microscopy (TEM), and beta-sheet-imaging probe. Aging treatment of glucagon resulted in the formation of fibrillar aggregates in time- and concentration-dependent manner, and FT-IR and FT-Raman analyses showed the spectral shift of amide I band, suggesting the conformational changes from alpha-helix to beta-sheet structure. Interestingly, secretin, having high sequential and secondary structural homology with glucagon, did not generate the fibrillar aggregates at the conditions tested. In addition, we evaluated the association state of glucagon at various pHs raging from pH 2.0 to 3.5 using CE. Based on the CE data, the rate constants of glucagon aggregation were calculated to be 0.002 +/- 0.004/h and 0.080 +/- 0.011/h for aging at pH 2.0 and 3.5, respectively, suggesting the pH dependence of self-association. CE showed the potential to separate and detect the glucagon aggregates and intermediates during aging process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364337     DOI: 10.1016/j.chroma.2005.11.130

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  5 in total

1.  Optimal control of blood glucose: the diabetic patient or the machine?

Authors:  Larry Brown; Elazer R Edelman
Journal:  Sci Transl Med       Date:  2010-04-14       Impact factor: 17.956

2.  Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study.

Authors:  Morey W Haymond; Maria J Redondo; Siripoom McKay; Martin J Cummins; Brett Newswanger; John Kinzell; Steven Prestrelski
Journal:  Diabetes Care       Date:  2016-02-09       Impact factor: 19.112

3.  Structural transitions and interactions in the early stages of human glucagon amyloid fibrillation.

Authors:  Balakrishnan S Moorthy; Hamed Tabatabaei Ghomi; Markus A Lill; Elizabeth M Topp
Journal:  Biophys J       Date:  2015-02-17       Impact factor: 4.033

Review 4.  Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon.

Authors:  Stephanie T Chung; Morey W Haymond
Journal:  J Diabetes Sci Technol       Date:  2014-08-26

5.  Characterization of seed nuclei in glucagon aggregation using light scattering methods and field-flow fractionation.

Authors:  Cindy C Hoppe; Lida T Nguyen; Lee E Kirsch; John M Wiencek
Journal:  J Biol Eng       Date:  2008-07-09       Impact factor: 4.355

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.